{
    "nctId": "NCT04962425",
    "briefTitle": "Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients",
    "officialTitle": "Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients",
    "overallStatus": "UNKNOWN",
    "conditions": "Cardiac Toxicity, Antitumor Drugs, Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 240,
    "primaryOutcomeMeasure": "Cardiac toxicity",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Female patients diagnosed with HER2-positive breast cancer treated in our hospital.\n2. Surgical treatment combined with chemotherapy or radiotherapy was completed according to NCCN guidelines, and trastuzumab standard treatment was received for at least half a year.\n\n(3) Cardiac function (including echocardiography or biomarkers) was assessed at least once within 3 months before trastuzumab treatment, and at least once during or after treatment was performed for heart-related tests.\n\n(4) Complete case data.\n\nExclusion Criteria:\n\n1. Patients who have not been properly treated with trastuzumab or have been treated for less than half a year;\n2. Patients who did not receive cardiac function assessment before trastuzumab treatment, during or after treatment;\n3. Patients whose case data were missing or lost to follow-up.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}